Indications
INDICATION

IMDELLTRA™ (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. …READ MORE

INDICATION

IMDELLTRA™ (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

NCCN

National Comprehensive
Cancer Network® (NCCN®)

Tarlatamab-dlle (IMDELLTRA™) IS NOW INCLUDED IN THE CLINICAL GUIDELINES FOR SCLC1

You are leaving
IMDELLTRAhcp.com

You are now leaving IMDELLTRAhcp.com and entering another Amgen website. Amgen is not adopting such content into this website.


Go back to IMDELLTRAhcp.com Leave the website

You are leaving
IMDELLTRAhcp.com

You are now leaving IMDELLTRAhcp.com and entering another external website. Amgen is not responsible for the content of the third party website and is not adopting such content into this website.


Go back to IMDELLTRAhcp.com Leave the website

Connect with an IMDELLTRA™ representative

Do you have questions about IMDELLTRA™ treatment?

Enter your information today and a representative will be in touch with you soon.

*Required Information
Enter valid Phone Number
Enter valid Email
Enter valid Address
Alternate address found. Please select one
Entered Address:
Suggested Address:
Submit

Thanks for signing up! Your request has been sent.

A representative will be in touch with you soon.

System Error. Please try after some time.

Back to Home